The Downside of Looking on the Bright Side: Viropharma's Optimism Hurts Vancocin Case
This article was originally published in RPM Report
Executive Summary
Viropharma’s challenge to FDA’s approval of generic versions of Vancocin hasn’t gotten very far in court. One reason: the company’s own statements to investors undercut one of the key components of a preliminary injunction suit.